ClinicalTrials.gg
TerminatedNCT03823703Updated Aug 31, 2022Results posted

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

A Phase 2 interventional study of Miricorilant and Placebo in Nonalcoholic Steatohepatitis (NASH), sponsored by Corcept Therapeutics. Terminated at 15 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-31.

Sponsored by Corcept Therapeutics · Phase 2, Interventional, and Treatment

Why this study was terminated
Suspended by sponsor, pending investigation of abnormal laboratory values in patients with NASH

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
402nd of 460
12 · median 56
Started
2020
with 38 others
Phase 2
192 of 547
15 open now
Registered
272nd of 547
by date
Lead sponsor
8 of 547
Corcept Therapeutics

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 402nd largest by enrollment of the 460 interventional ones that give a count, is one of 39 that started in 2020, is one of 192 in phase 2, and was the 272nd registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This phase 2, double blind, placebo-controlled, randomized study is to assess the safety and efficacy of miricorilant (CORT118335) in patients with presumed Nonalcoholic Steatohepatitis (NASH).

Read the detailed description

This is a randomized, double-blind, placebo-controlled study that assessed the safety efficacy and pharmacokinetics (PK) of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). Patients who meet the criteria for Study CORT118335-860 were randomized on Day 1 to receive 900 mg miricorilant, 600 mg miricorilant, or placebo for 12 weeks.

Due to observations related to safety, the study was terminated prior to completion and study objectives, endpoints, and procedures were modified as specified in the protocol.

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)

Keywords

  • Nonalcoholic Steatohepatitis
  • NASH
  • Nonalcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of NASH based on a obtained within the last year OR
  • Have a diagnosis of presumed NASH based on blood tests and scans

Exclusion criteria

Exclusion Criteria:

  • Have participated in another clinical trial within the last year and received active treatment for NASH
  • Have participated in another clinical trial for any other indication within the last 3 months
  • Are pregnant or lactating women
  • Have a \<18 kg/m\^2
  • Have had liver transplantation or plan to have liver transplantation during the study
  • Have type 1 diabetes or poorly controlled type 2 diabetes.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Miricorilant- 900 mg

    Participants received 900 mg miricorilant (6 miricorilant tablets of 150 mg) orally once daily.

    Drug: Miricorilant

  • Experimental
    Miricorilant- 600 mg

    Participants received 600 mg miricorilant (4 miricorilant tablets of 150 mg and 2 placebo tablets) orally once daily.

    Drug: Miricorilant · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants received 6 placebo tablets orally once daily.

    Drug: Placebo

Interventions

  • Tablets taken orally

    Also known as: CORT118335

  • DrugPlacebo

    Placebo tablets

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction

    The change from baseline in liver fat content (LFC) by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) for each miricorilant dose level (600 mg, 900 mg) versus placebo was assessed. MRI-PDFF was performed to determine the degree of LFC reduction. The relative change is defined for each participant as %: (\[Post-Baseline LFC-Baseline LFC\]/Baseline LFC) × 100. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

    Time frame: Baseline and up to ~Day 95

Secondary outcomes

  1. Number of Participants Achieving a Relative Reduction From Baseline in LFC of ≥30% by MRI-PDFF

    The number of participants (defined as responders) with a ≥30% reduction in LFC from baseline by treatment group as assessed by MRI-PDFF. The number of participants with a reduction in LFC from baseline of \<30% were defined as non-responders. MRI-PDFF was performed at screening and up to 33 days after last dose of study drug. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

    Time frame: Baseline and up to ~Day 95

  2. Change From Baseline in Aspartate Aminotransferase

    The change in aspartate aminotransferase (AST) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

    Time frame: Baseline and Week 6

  3. Change From Baseline in Alanine Aminotransferase

    The change in serum alanine aminotransferase (ALT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

    Time frame: Baseline and Week 6

  4. Change From Baseline in Gamma-glutamyl Transferase

    The change in gamma-glutamyl transferase (GGT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

    Time frame: Baseline and Week 6

  5. Change From Baseline in Propeptide of Type III Collagen

    The change in serum propeptide of Type III collagen (pro-C3) from baseline at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

    Time frame: Baseline and Week 6

  6. Change From Baseline in Enhanced Liver Fibrosis Score

    The change in enhanced liver fibrosis (ELF) from baseline for each treatment group at the Week 6 visit is summarized. The ELF score combines 3 serum biomarkers (hyaluronic acid, tissue inhibitor of metalloproteinases-1 \[TIMP-1\] and type III procollagen \[PIIINP\]) which have been shown to correlate with the degree of liver fibrosis assessed by liver biopsy. Each of these markers is measured by an immunoassay and an ELF score is generated \[ELF=2.278+0.851 ln(HA)+0.751 ln(PIIINP)+0.394 ln(TIMP-1)\], from which a level of fibrosis severity can be determined; higher ELF scores are associated with worsening liver fibrosis. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

    Time frame: Baseline and Week 6

Other outcomes

  1. Number of Participants With a Relative Reduction in Liver Fat Content ≥50% by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) for Miricorilant Versus Placebo

    Time frame: Baseline and up to ~Day 95

  2. Number of Participants With Complete Resolution in Liver Fat by MRI-PDFF for Miricorilant Versus Placebo

    Time frame: Baseline and up to ~Day 95

07

Results

Posted Aug 31, 2022
Limitations and caveats
Due to observations related to safety, the study was terminated by the Sponsor prior to completion. The sample size at the time of study termination did not support formal tests to assess statistical differences between treatment groups, and therefore, no efficacy analyses specified in the protocol were performed. Descriptive statistics for efficacy endpoints are provided, but since no patient reached the Week 12 visit, and therefore, descriptive statistics at Week 12 are not presented.

Participant flow

Participant flow — Overall Study
MilestoneMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Started354
Treated354
Completed000
Not completed354
Withdrew: Sponsor request034
Withdrew: Adverse event310
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryRelative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction

The change from baseline in liver fat content (LFC) by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) for each miricorilant dose level (600 mg, 900 mg) versus placebo was assessed. MRI-PDFF was performed to determine the degree of LFC reduction. The relative change is defined for each participant as %: (\[Post-Baseline LFC-Baseline LFC\]/Baseline LFC) × 100. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

Time frame:
Baseline and up to ~Day 95
Reported as:
Mean · Percent change
Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction
Percent changeMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Relative Change From Baseline in Liver Fat Content Assessed by Magnetic Resonance Imaging-Proton Density Fat Fraction-50.28 ± 13.723-22.94 ± 71.9434.63 ± 5.232
SecondaryNumber of Participants Achieving a Relative Reduction From Baseline in LFC of ≥30% by MRI-PDFF

The number of participants (defined as responders) with a ≥30% reduction in LFC from baseline by treatment group as assessed by MRI-PDFF. The number of participants with a reduction in LFC from baseline of \<30% were defined as non-responders. MRI-PDFF was performed at screening and up to 33 days after last dose of study drug. Due to observations related to safety, the study was terminated. If the participant had at least 6 weeks of treatment, the assessment was completed at the early termination visit. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

Time frame:
Baseline and up to ~Day 95
Reported as:
Count of participants · Participants
Number of Participants Achieving a Relative Reduction From Baseline in LFC of ≥30% by MRI-PDFF
ParticipantsMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Responders with a reduction in LFC from baseline of ≥30%310
Non-responders with a reduction in LFC from baseline of <30%012
SecondaryChange From Baseline in Aspartate Aminotransferase

The change in aspartate aminotransferase (AST) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

Time frame:
Baseline and Week 6
Reported as:
Mean · units per liter (U/L)
Change From Baseline in Aspartate Aminotransferase
units per liter (U/L)Miricorilant- 900 mgMiricorilant- 600 mgPlacebo
Change From Baseline in Aspartate Aminotransferase346.0 ± NA321.0 ± NA-9.5 ± 3.54
SecondaryChange From Baseline in Alanine Aminotransferase

The change in serum alanine aminotransferase (ALT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

Time frame:
Baseline and Week 6
Reported as:
Mean · U/L
Change From Baseline in Alanine Aminotransferase
U/LMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Change From Baseline in Alanine Aminotransferase810.0 ± NA826.0 ± NA-16 ± 2.83
SecondaryChange From Baseline in Gamma-glutamyl Transferase

The change in gamma-glutamyl transferase (GGT) from baseline for each treatment group at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

Time frame:
Baseline and Week 6
Reported as:
Mean · U/L
Change From Baseline in Gamma-glutamyl Transferase
U/LMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Change From Baseline in Gamma-glutamyl Transferase29.0 ± NA82.0 ± NA-26.0 ± 31.11
SecondaryChange From Baseline in Propeptide of Type III Collagen

The change in serum propeptide of Type III collagen (pro-C3) from baseline at the Week 6 visit is summarized. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

Time frame:
Baseline and Week 6
Reported as:
Mean · μg/L
Change From Baseline in Propeptide of Type III Collagen
μg/LMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Change From Baseline in Propeptide of Type III Collagen4.0 ± NA—-1.65 ± 2.475
SecondaryChange From Baseline in Enhanced Liver Fibrosis Score

The change in enhanced liver fibrosis (ELF) from baseline for each treatment group at the Week 6 visit is summarized. The ELF score combines 3 serum biomarkers (hyaluronic acid, tissue inhibitor of metalloproteinases-1 \[TIMP-1\] and type III procollagen \[PIIINP\]) which have been shown to correlate with the degree of liver fibrosis assessed by liver biopsy. Each of these markers is measured by an immunoassay and an ELF score is generated \[ELF=2.278+0.851 ln(HA)+0.751 ln(PIIINP)+0.394 ln(TIMP-1)\], from which a level of fibrosis severity can be determined; higher ELF scores are associated with worsening liver fibrosis. Due to the small sample size, no formal tests were performed to assess statistical differences between treatment groups.

Time frame:
Baseline and Week 6
Reported as:
Mean · ELF score
Change From Baseline in Enhanced Liver Fibrosis Score
ELF scoreMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Change From Baseline in Enhanced Liver Fibrosis Score1.050 ± NA—0.225 ± 0.459
Other pre-specifiedNumber of Participants With a Relative Reduction in Liver Fat Content ≥50% by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) for Miricorilant Versus Placebo
Time frame:
Baseline and up to ~Day 95
Reported as:
Count of participants · Participants
Number of Participants With a Relative Reduction in Liver Fat Content ≥50% by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) for Miricorilant Versus Placebo
ParticipantsMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Responders110
Non-Responders212
Other pre-specifiedNumber of Participants With Complete Resolution in Liver Fat by MRI-PDFF for Miricorilant Versus Placebo
Time frame:
Baseline and up to ~Day 95
Reported as:
Count of participants · Participants
Number of Participants With Complete Resolution in Liver Fat by MRI-PDFF for Miricorilant Versus Placebo
ParticipantsMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Responders010
Non-Responders312

Adverse events

Collected over Up to ~Day 95 for all cause mortality, serious adverse events and other non-serious treatment-emergent adverse events (TEAEs) during the study period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Miricorilant- 900 mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Miricorilant- 600 mg0/5 (0%)0/5 (0%)5/5 (100%)
Placebo0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent serious events
Most frequent serious events
EventMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Drug-induced liver injuryHepatobiliary disorders2/30/50/4
Alanine aminotransferase increasedInvestigations1/30/50/4
Aspartate aminotransferase increasedInvestigations1/30/50/4
Most frequent other events
Showing 10 of 19
Most frequent other events
EventMiricorilant- 900 mgMiricorilant- 600 mgPlacebo
Influenza like illnessGeneral disorders2/30/50/4
Alanine aminotransferase increasedInvestigations2/31/50/4
HeadacheNervous system disorders1/32/50/4
EosinophiliaBlood and lymphatic system disorders1/30/50/4
VertigoEar and labyrinth disorders1/30/50/4
Abdominal distensionGastrointestinal disorders1/31/50/4
ConstipationGastrointestinal disorders1/30/50/4
NauseaGastrointestinal disorders1/30/50/4
VomitingGastrointestinal disorders1/30/50/4
MalaiseGeneral disorders1/30/50/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Miricorilant- 900 mgMiricorilant- 600 mgPlaceboTotal
Mean55.7 ± 14.7454.2 ± 19.8743.3 ± 15.1550.9 ± 16.68
Sex: Female, Male
Sex: Female, Male(Participants)Miricorilant- 900 mgMiricorilant- 600 mgPlaceboTotal
Female2226
Male1326
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Miricorilant- 900 mgMiricorilant- 600 mgPlaceboTotal
Hispanic or Latino2204
Not Hispanic or Latino1348
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Miricorilant- 900 mgMiricorilant- 600 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0011
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White35311
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Miricorilant- 900 mgMiricorilant- 600 mgPlaceboTotal
United States35412
Liver Fat Content (LFC) Assessed by MRI-PDFF
Liver Fat Content (LFC) Assessed by MRI-PDFF(Percentage of liver fat content)Miricorilant- 900 mgMiricorilant- 600 mgPlaceboTotal
Mean24.57 ± 6.03815.70 ± 6.53619.93 ± 8.75019.33 ± 7.526
Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) & Gamma Glutamyl Transferase (GGT)
Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) & Gamma Glutamyl Transferase (GGT)(Units/Liter (U/L))Miricorilant- 900 mgMiricorilant- 600 mgPlaceboTotal
AST35.7 ± 8.1425.6 ± 12.7631 ± 4.0829.9 ± 9.68
ALT52.3 ± 15.6333.2 ± 15.9454.0 ± 12.1144.9 ± 16.86
GGT52.7 ± 19.6326.2 ± 9.2059.0 ± 50.2943.8 ± 32.20
Propeptide of Type III Collagen (Pro-C3)
Propeptide of Type III Collagen (Pro-C3)(micrograms/liter (μg/L))Miricorilant- 900 mgMiricorilant- 600 mgPlaceboTotal
Mean16.13 ± 5.35011.20 ± 2.18913.73 ± 4.72713.28 ± 4.159

1 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • Site 207
    Chandler, Arizona 85224, United States
  • Site 208
    Glendale, Arizona 85306, United States
  • Site 209
    Tucson, Arizona 85712, United States
  • Site 227
    Los Angeles, California 90057, United States
  • Site 214
    Panorama City, California 91402, United States
  • Site 233
    Santa Ana, California 92704, United States
  • Site 234
    Port Orange, Florida 32127, United States
  • Site 210
    Sarasota, Florida 34240, United States
  • Site 228
    Kansas City, Missouri 61434, United States
  • Site 232
    East Syracuse, New York 13057, United States
  • Site 211
    Austin, Texas 78757, United States
  • Site 213
    Edinburg, Texas 78539, United States
  • Site 215
    Edinburg, Texas 78539, United States
  • Site 212
    San Antonio, Texas 78229, United States
  • Site 226
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2020 to primary completion in Apr 2021, 5 months.

Results were first posted in Aug 2022, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2019
First posted
Jan 30, 2019
StartActual
Nov 4, 2020
Primary completionActual
Apr 5, 2021
CompletionActual
Apr 5, 2021
Results first posted
Aug 31, 2022
Last update
Aug 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03823703
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Nov 4, 2020
Primary completion
Apr 5, 2021
Completion
Apr 5, 2021
Results posted
Aug 31, 2022
Last update
Aug 31, 2022

Study contacts

Director
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion